市場調查報告書
商品編碼
391459

全球泌尿道感染(UTI)治療藥市場 - 成長,趨勢,預測(2017年∼2022年)

Urinary Tract Infection Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 115 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

美國女性的5人有1人罹患泌尿道感染(UTI)。還有2002年中,起因於泌尿道感染的住院數量報告是150萬件。

本報告提供全球泌尿道感染(UTI)治療藥市場相關調查,市場概要,各治療類型、症狀、地區的市場趨勢,市場規模的變化與預測,市場成長、阻礙因素以及市場機會分析,市場佔有率,競爭情形,主要企業的簡介等,全面性資訊。

目錄

第1章 簡介

  • 調查的成果
  • 市場定義
  • 調查對象期間及預測
  • 一般調查的前提條件
  • 報告概要

第2章 調查方法

  • 簡介
  • 分析方法
  • 調查的時間軸
  • 調查的階段
    • 2次調查
    • 討論指南
    • 市場工程&計量經濟學模式

第3章 摘要整理

第4章 主要推論

第5章 市場及產業的趨勢

  • 目前市場方案
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第6章 市場動態

  • 市場成長要素
    • 發病率高和診斷的正確性
    • 複合治療藥
    • 成藥的適應症
  • 市場阻礙因素
    • 低價格的學名藥的競爭激烈化
  • 市場機會
  • 主要課題

第7章 全球泌尿道感染(UTI)治療藥市場

  • 各治療藥類型
    • 青霉素 & 複合治療藥
    • 奎諾酮類抗生素(Quinolones)類
    • 頭孢菌素
    • Aminoglycosides抗體
    • 磺胺類藥物
    • Azoles & Amphotericin B
    • 四環黴素
    • 硝基餡餅
    • 其他
  • 各症狀
    • 複雜性UTI
    • 復發性複雜性UTI
    • 非複雜性UTI
    • 神經原因性膀胱

第8章 全球泌尿道感染(UTI)治療藥市場:各地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英語
    • 法國
    • 義大利
    • 西班牙、葡萄牙
    • 斯堪地那維亞各國
    • 荷比盧三國
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲、紐西蘭
    • 韓國
    • 其他
  • 中東、非洲
    • 波灣合作理事會(GCC)
    • 南非
    • 其他
  • 南美
    • 巴西
    • 阿根廷
    • 其他

第9章 競爭情形

  • M&A分析
  • 新產品的銷售
  • 協定,合作,夥伴關係

第10章 企業簡介

  • Pfizer
  • Boehringer Ingelheim
  • Bayer
  • GlaxoSmithKline
  • Novartis
  • Hoffman-La Roche
  • Johnson & Johnson
  • AstraZeneca
  • Cipla
  • Cubist Pharmaceuticals
  • Osel Inc
  • Novexel
  • MerLion Pharmaceuticals
  • 其他

第11章 分析師的投資機會預測

第12章 市場未來展望

目錄
Product Code: 46354

The Urinary Tract Infection Therapeutics Market is expected to register a CAGR of 4.1% during the forecast period. Certain factors that are driving the market growth include the increasing prevalence of diabetes and kidney stones and the launch of combination drugs.

Key Highlights

  • According to a study published in Advances in Urology 2018, Kidney stone disease is an increasing urological disorder of human health which is affecting about 15% of the world population and it affects all age groups but occurs more frequently in men than in women within the age of 20-49 years. Moreover, during a lifetime, approximately 7% of women and 13% of men will develop a kidney stone.
  • Therefore, with the increasing prevalence of diabetes and kidney stones, the number of cases of urinary tract infection (UTI) increases, which in turn, increases the demand for drugs, thus, driving the global urinary tract infection therapeutics market.
  • Additionally, the launch of more efficient combination drugs and increasing geriatric population are expected to boost the growth of the urinary tract infection therapeutics market.
  • However, according to the Center for Education & Research on Therapeutics, over 2 million cases of adverse drug reactions (ADRs) are reported every year, leading to approximately 100,000 deaths.
  • According to the FDA, it is estimated that, in the United States, each year, over 350,000 ADRs occur in nursing homes alone.
  • With an increase in the number of cases of ADRs being reported, globally, there is an awareness among the population about the adoption of drugs, which is acting as a major restraint for the urinary tract infection therapeutics market.
  • Additionally, the lack of awareness about the prevalence of UTIs in the developing and underdeveloped countries is also restraining the growth of the market.

Key Market Trends

Complicated UTIs Segment is Expected to Hold a Major Market Share in the Urinary Tract Infection Therapeutics Market

The prevalence of complicated UTI is expected to increase in the future, owing to the rise in drug-resistant bacteria and excessive use of antibiotics. A vast majority of physicians prescribe quinolones to treat complicated UTI cases. Cephalosporin is the second-most common drug prescribed for complicated UTI cases.

According to the American Academy of Family Physicians (AAFP), kidney stones are a common disorder, with an annual incidence of eight cases per 1,000 adults. Moreover, around 13% of men and 7% of women develop a kidney stone in their lifetime and the overall incidence of urinary retention is 4.5 to 6.8 per 1,000 men, per year, in the United States. Overall, the prevalence of complicated UTI is set to increase during the forecast period, mainly owing to the increasing bacterial resistance in UTI cases and rise in recurrence rate for UTI.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

The region is experiencing a drastic increase in innovations related to diagnostic methodologies used for UTIs. In recent events, during a routine checkup for UTI, a woman was observed to be infected by E. coli that showed resistance to the last-resort antibiotic, Colistin. The discovery of Colistin-resistant bacteria was considered a major issue. In addition to that, the CDC, in collaboration with other organizations, developed guidelines for the prevention of catheter-associated UTIs and other types of healthcare-associated infections in the United States.

Furthermore, According to the Queensland Pediatric Factsheet 2019, estimates that approximately 1 in 10 girls and 1 in 50 boys will suffer from a urinary tract infection by seven years of age. Infections in children under one year are more common in boys but in older children infections are more common in girls. Thus, owing to the above factors the market is expected to show growth in the coming years.

Competitive Landscape

The urinary tract infection therapeutics market is fragmented competitive and consists of a number of major players. Some of the companies which are currently dominating the market are AstraZeneca, Bayer AG, Cipla Inc., GlaxoSmithKline PLC, Shionogi & Co., Ltd, Novartis AG, and Pfizer, and others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Diabetes and Kidney Stones
    • 4.2.2 Launch of Combination Drugs
  • 4.3 Market Restraints
    • 4.3.1 Adverse Effects Associated with the Use of Medication
    • 4.3.2 Lack of Awareness in the Developing and Underdeveloped Countries
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Drug
    • 5.1.1 Penicillin and Combinations
    • 5.1.2 Quinolones
    • 5.1.3 Cephalosporin
    • 5.1.4 Azoles and Amphotericin B
    • 5.1.5 Nitrofurans
    • 5.1.6 Other Drugs (Aminoglycoside Antibodies, Sulphonamides, Tetracycline, etc.)
  • 5.2 Indication
    • 5.2.1 Complicated UTI
    • 5.2.2 Uncomplicated UTI
    • 5.2.3 Other Indications (Recurring Complicated UTI, Neurogenic Bladder Infection, etc.)
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AstraZeneca
    • 6.1.2 Bayer AG
    • 6.1.3 Cipla Inc.
    • 6.1.4 GlaxoSmithKline PLC
    • 6.1.5 Shionogi & Co., Ltd
    • 6.1.6 Novartis AG
    • 6.1.7 Pfizer

7 MARKET OPPORTUNITIES AND FUTURE TRENDS